Atlas Bio raises $12.5 million for virtual drug trials
Oct 27, 2026
Healthcare
Araceli Biosciences Adds Investor to $4.5 Million Round
Nov 12, 2026
Drug discovery imaging company Araceli Biosciences said Jeff Swickard has joined the investors in its recently closed $4.5 million financing.
Araceli Biosciences, which makes high-throughput cellular imaging systems for drug discovery, said Jeff Swickard has joined the investors in its recently closed $4.5 million financing, the company said in a press release. Araceli projects its 2026 revenue at six times the level of two years ago.
Its Endeavor platform helps researchers monitor how human cells respond to drug compounds, supporting the shift toward New Approach Methodologies that replace some animal testing with human cell-based assays. Araceli says the work fits pharmaceutical companies' move to a tech-forward, AI-driven approach to drug discovery, and that 10 of the world's top 20 drug makers use its technology.
The Tigard, Oregon company plans to launch consumable products for its installed base, with a broader rollout in 2027.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Nov 12 Worker.ai Acquires DeltaGen and Launches Small Business Operating System Nov 12 Mondrio Raises $3.75 Million for AI B2B Pricing Agents Nov 12 Elligint Health Acquires Israeli AI Care Management Startup Laguna Nov 12 Rox Raises $100 Million at $1.3 Billion Valuation Nov 12 SE3 Raises $30 Million for Military Drone AIMore from Life Sciences
Nov 12 DarioHealth Q3 Revenue Rises 6% to $5.3 Million Nov 12 Elligint Health Acquires Israeli AI Care Management Startup Laguna Nov 12 Biomatter Raises $18 Million for AI Enzyme Design Nov 12 BioMap Announces 11 AI Life Science Collaborations Nov 11 Optum and Alameda Alliance Partner on AI Claims AutomationFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Oct 29, 2026
Healthcare
Adsilico Raises £10 Million for Virtual Medical Device Testing
Oct 27, 2026
Healthcare
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Oct 29, 2026
Funding
Switchpoint Bio raises $5.3 million for AI epigenomics platform
Nov 11, 2026
Funding
Azra AI Acquires Blackford Analysis
Oct 20, 2026
Acquisitions
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.